During the recent years, the median survival of patients with pathologic process body part cancer has improved dramatically. Gastroenterological interventions ar oftentimes carried throughout the unwellness course, and familiarity with the assorted facet effects of regimens that ar normally employed in these patients is needed. Bevacizumab, a humanized antibody targeting VEGF, includes a dominant role within the treatment of pathologic process carcinoma. it's been shown in irregular trials to enhance overall survival compared to straightforward treatment. Yet, this profit is counterpoised by a distinct safety profile compared to classic therapy regimens, that is doubtless serious and fatal. The facet effects embody impaired wound healing, intestine perforation, fistula formation, hemorrhage, thrombosis, symptom and cardiovascular disease. this review focuses on the medical specialty, management and prophetic price of bevacizumab’s toxicity.
Juan Pablo Marquez
Editorial: Research & Reviews: Medical and Clinical Oncology
Juan Pablo Marquez
Editorial: Research & Reviews: Medical and Clinical Oncology
Hemish H Kania
Editorial: Research & Reviews: Medical and Clinical Oncology
Hemish H Kania
Editorial: Research & Reviews: Medical and Clinical Oncology
Karlo Pan Fidel
Editorial: Research & Reviews: Medical and Clinical Oncology
Karlo Pan Fidel
Editorial: Research & Reviews: Medical and Clinical Oncology
Menu
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi